Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talibegron SCHEMBL3699503 | 1.00 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL6060362 | 1.00 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL1230810 | 0.99 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL8976330 | 0.99 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976026 | 0.90 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976032 | 0.90 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976399 | 0.89 | ALOX15 (0.78) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976317 | 0.89 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976435 | 0.89 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976401 | 0.89 | ALOX15 (0.78) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | claimed |
| EP-4132914-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | The Regents of the University of California (US) | 2023-02-15 | — | — | EP | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-104427985-A | Pharmaceutical combination for the treatment of metabolic disorders | BOEHRINGER INGELHEIM INT | 2015-03-18 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2124970-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008087198-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0516349-B1 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | claimed |
| US-5393779-A | Anti-obesity, hypoglycemic, adrenergic blocking agents | ZENECA LIMITED (GB) | 1995-02-28 | — | — | US | claimed |
| EP-0516349-A2 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | TFAM, FABP4, CPT2 | ALOX15 627/4885ADRB3 83/4885ADRB1 106/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ALOX15 1963/4885ADRB3 4025/4885ADRB1 4090/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | ALOX15 1062/4885ADRB3 3450/4885ADRB1 3375/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ALOX15 1963/4885ADRB3 4025/4885ADRB1 4090/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ALOX15 1963/4885ADRB3 4025/4885ADRB1 4090/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ALOX15 1963/4885ADRB3 4025/4885ADRB1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.